Secondary analysis of three phase 3 brivaracetam trials in drug-resistant epilepsy: a new composite outcome (Epilepsy-DOOR) showed benefit of 100 mg over placebo in one trial (win odds 1.42) but no significant benefit in the other two.
Secondary analysis
Vivash et al. The Epilepsy-Desirability of Outcome Ranking (DOOR) as a Multi-Faceted Consumer-Informed Outcome Measure for Epilepsy Clinical Trials